ALFA Finder| Revenue growth | FY26: 36% YoY; FY27 Target: ₹650 Cr (approx 30% growth). |
|---|---|
| Margins | Expanding: EBITDA margin up from 22% (FY25) to 24% (FY26). |
| Demand visibility | Strong, backed by 700+ filings and 100+ global clients. |
| Management confidence | High, targeting 3x profit growth vs revenue through high-margin complex molecules. |
Growth
FY26 revenue grew 36% YoY to ₹503 Cr; PAT surged 72% to ₹67.4 Cr. EBITDA margins expanded to 24%.
Outlook
Targeting 30-35% topline growth in FY27 (₹650 Cr). Unit 6 Hormone plant completion by Q3CY26; Biologics commercialization H1FY27.
Risks
Regulatory compliance risks across 70+ countries; high concentration in Unit 1 (60% revenue); execution risk in Unit 6.
Earnings Call filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,020.00
- Market cap
- ₹4,171 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.5×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.